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ABSTRACT 
Human infection by Zika virus (ZIKV) during pregnancy can lead to vertical transmission and 
fetal aberrations, including microcephaly. Prophylactic administration of antibodies can diminish 
or prevent ZIKV infection in animal models, but whether passive immunization can protect 
nonhuman primates and their fetuses during pregnancy has not been determined. Z004 and Z021 
are neutralizing monoclonal antibodies to domain III of the envelope (EDIII) of ZIKV. Together 
the two antibodies protect nonpregnant macaques against infection even after Fc modifications to 
prevent antibody-dependent enhancement in vitro (ADE) and extend their half-lives. Here we 
report on prophylactic co-administration of the Fc-modified antibodies to pregnant rhesus 
macaques challenged 3 times with ZIKV during first and second trimester. The two antibodies did 
not entirely eliminate maternal viremia but limited vertical transmission protecting the fetus from 
neurologic damage. Thus, maternal passive immunization with two antibodies to EDIII can shield 
primate fetuses from the harmful effects of ZIKV. 
 
 
Significance statement: 
Zika virus (ZIKV) infection during pregnancy can cause fetal abnormalities. Vaccines against ZIKV are 
under development, but because of potential safety concerns due to disease enhancing antibodies, and the 
time required by active immunization to induce protective antibodies, there is a need to explore 
alternative strategies. Recombinant monoclonal antibodies can be modified to prevent enhancement of 
infection, and thus could be an efficacious and safe alternative to vaccines to confer rapid protection. We 
show that prophylactic administration of two engineered antibodies, Z004 and Z021, to pregnant 
macaques partially protects against fetal neurologic damage and limits vertical transmission of ZIKV. 
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ZIKV is a mosquito-borne flavivirus that in humans is often asymptomatic but can manifest as febrile 
illness and rarely as neurologic disease (1, 2). Although ZIKV was discovered in 1947, its devastating 
effects on fetal health were only recognized during the 2015 outbreak in the Americas (3). ZIKV infection 
during pregnancy can result in a range of birth defects that predominantly involve the central nervous 
system including microcephaly (4-6). The rate of adverse outcomes varies but can surpass 40% in some 
regions (7-10). Similar consequences are observed in macaques, where experimental infection during 
gestation can lead to fetal neuropathology and demise (11-13). 
Although the path to approval is challenging due to the waning epidemic, several ZIKV vaccine 
candidates have entered clinical trials (14, 15). In preclinical settings, vaccine efficacy was demonstrated 
in mice and macaques (16, 17), including mouse and macaque pregnancy models (18-21). One of the 
potential issues with vaccination is that active immunization regimens require time to induce protective 
immunity and therefore vaccination after conception may be ineffective in preventing fetal disease in the 
setting of an active outbreak. In addition, there is concern about vaccine-mediated enhancement because 
features of maternal antibodies that enhance ZIKV infection in vitro are associated with an increased risk 
of human microcephaly and other neurologic defects in humans and macaques (22). Thus, there is a need 
to develop strategies to limit maternal and fetal pathology that are rapid, effective and safe. 
 
Results 
The combination of human IgG1 monoclonal antibodies Z004 and Z021 significantly reduces plasma 
viral loads and prevents emergence of viral escape mutations in nonpregnant rhesus macaques challenged 
with a super-physiologic dose of ZIKV intravenously (105 plaque-forming units, PFU) (23). Similar 
results were obtained when the antibodies were modified to prevent ADE in vitro by mutations that 
abrogate Fc-g receptor engagement (GRLR; (23, 24)).  
To evaluate the protective effect of these antibodies against what is considered to be a more 
physiologic dose and route of administration, we administered Z004GRLR + Z021GRLR to macaques 24 
hours before subcutaneous inoculation with 103 PFU of ZIKV (Fig. 1A) (25, 26). In untreated controls, 
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plasma viremia peaked on day 4-5 after infection, reaching between 105-107 RNA copies/ml (n=4; black 
in Fig. 1B). In contrast, plasma viremia was undetectable in 3 out of 6 antibody treated macaques, and it 
was lower and delayed in the remaining 3 animals (green in Figs. 1B-D). Since ZIKV can be detected in 
macaque tissues even when absent from plasma (13, 27), we measured viral RNA in a panel of 17 tissues 
(Fig. 2). Viral RNA was evident in multiple tissues in control animals as well as in the 3 animals that 
showed low and delayed viremia after infection (Fig. 2A, right). In contrast, viral RNA was low or 
undetectable in tissues from macaques with no detectable plasma viremia (Figs. 2A, left, and B). Thus, 
prophylactic administration of Z004GRLR + Z021GRLR prevents or reduces viral accumulation in plasma 
and tissues upon low-dose ZIKV challenge. 
The half-life of Z004 and Z021 can be extended by altering the antibody’s Fc domain (LS 
mutation; (28, 29)) without altering ZIKV neutralizing activity in vitro or in vivo (23). To determine 
whether Z004GRLR/LS + Z021GRLR/LS remain efficacious in macaques, we administered the combination 
before low-dose subcutaneous challenge with ZIKV. Z004GRLR/LS + Z021GRLR/LS showed extended half-
lives and their levels in plasma remained more than 4 logs above the in vitro inhibitory concentration 
throughout the monitoring period (Fig. S1). The treatment prevented plasma viremia in 2 of 6 macaques; 
one macaque had a single episode of low-level viremia (less than 103 viral RNA copies/ml on day 2 post 
infection), and the remaining 3 had lower and delayed viral loads (orange in Figs. 1B-D) compared to 
untreated controls. The macaques that developed plasma viremia after administration of Z004GRLR + 
Z021GRLR or Z004GRLR/LS + Z021GRLR/LS had viruses with mutations in the EDIII region: T309A, 
T309A/V330L, T309I/V330L and V330L (Figs. 3A-C). To determine whether these substitutions confer 
resistance to the antibodies, we produced reporter virus particles (RVPs; (30)) with these mutations and 
evaluated them for sensitivity to the 2 antibodies (Fig. 3D). Both antibodies retained potency against 
RVPs containing the V330L mutation, which was also found in untreated control animals (Fig. 3A). This 
mutation is located outside the epitope of either antibody (Fig. 3B). Although T309 is in the epitope of 
both antibodies (Figs. 3B and C), its mutations affected the potency of Z021 alone. Since T309 mutations 
did not alter ZIKV sensitivity to the combination of antibodies in vitro, they are unlikely to represent 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity.preprint (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for this. http://dx.doi.org/10.1101/2020.01.31.926899doi: bioRxiv preprint first posted online Feb. 2, 2020; 
  5 
virus escape (Fig. 3D). Consistent with these findings, the mutations involved residues other than those 
altered in the viruses emerging from macaques treated with the individual antibodies (E393 and K394 
with Z004, and T335 with Z021; (23) and Fig. S2). We conclude that Z004GRLR/LS + Z021GRLR/LS prevent 
emergence of viral escape variants found with monotherapy ((23) and Fig. S2) and are as efficacious as 
their GRLR counterparts against ZIKV in macaques. 
 ZIKV infection of pregnant macaques is associated with fetal demise and neuropathology  (11-
13). To evaluate the effect of anti-ZIKV antibodies on fetal development and health in pregnant primates, 
we performed timed breeding experiments and challenged the dams 3 times with 103 PFU of ZIKV 
subcutaneously on gestational days (GD) 30, GD 60 and GD 90, which corresponds to 1st and 2nd 
trimester (normal gestation of rhesus macaques is ~165 days) (21). Macaques in the treatment group 
received intravenous infusions of Z004GRLR/LS + Z021GRLR/LS antibodies 24 hours before each virus 
challenge (Fig. 4A). Both dam and fetus were closely monitored; animals were euthanized near the end of 
gestation for detailed tissue analysis (Tables S1 and S2).  During this whole observation period, human 
IgG plasma levels remained 3 logs or higher than the in vitro inhibitory concentration (see Methods and 
Fig. S3). Untreated macaques develop plasma viremia that peaks between days 2-5 after the first ZIKV 
inoculation (Fig. 4B, left; (21)). In contrast, out of the 8 antibody-treated dams, 3 had no detectable 
viremia, while 4 other animals had delayed peak viremia on days 7 (n=1) or 21 (n=3) after the first 
inoculation and a 5th developed peak viremia on GD90, 30 days after the second ZIKV inoculation (Fig. 
4B, right).  In addition, viremia was significantly lower and of shorter duration in antibody-treated dams 
(Figs. 4 B-F).  Fetal death (i.e., no heartbeat on ultrasound) was detected in 2 control animals (C03 and 
C07) on GD 35 and 60 (i.e., 5 and 30 days after the first ZIKV inoculation), with detectable viral RNA in 
placental and fetal tissues (21). Fetal death was observed on GD51 in one of the antibody-treated 
macaques (AB02). This occurred one week after undergoing routine amniocentesis and was coincident 
with a sudden spike of maternal viremia (>105 RNA copies/ml; Fig. 4B) and ZIKV in the amniotic fluid 
(104 RNA copies/ml) and placental-amniotic tissues (>104 RNA copies/g tissue). In the antibody-treated 
pregnant dams, mutations in the EDIII region of the emerging viruses were similar to the previously 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity.preprint (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for this. http://dx.doi.org/10.1101/2020.01.31.926899doi: bioRxiv preprint first posted online Feb. 2, 2020; 
  6 
observed mutations that did not alter sensitivity to the antibodies in combination and therefore are 
unlikely to represent escape (Fig. 3 and Fig. S4). We conclude that the Z004GRLR/LS + Z021GRLR/LS 
combination prevents or significantly reduces maternal viral loads during pregnancy. 
Amniocentesis was performed regularly to monitor potential ZIKV transmission to the placental-
fetal compartment. Six control animals (50%) had detectable ZIKV RNA in at least 1 amniotic fluid 
sample. In contrast, except for antibody-treated animal AB02 at time of fetal death, none of the other 
antibody-treated animals had detectable vRNA in amniotic fluid samples (Fig. S5). Since vertical 
transmission of ZIKV can cause congenital Zika syndrome, we examined the fetuses in the pregnancies 
that reached term. Fetal body, placenta, brain and other fetal organ weights were indistinguishable 
between controls and treatment groups (Fig. S6). In 9 of the 10 control untreated fetuses that made it to 
the end of gestation, ZIKV RNA was detected in at least one of the 17 examined tissues. These include 
the maternal-fetal interface, lymphoid, cardio-pulmonary, urinary, gastrointestinal and central nervous 
systems, and the skin (average of 6 ZIKV RNA positive tissues per fetus; Fig. 5A). In contrast, viral RNA 
was undetectable in the same fetal tissues from the 7 antibody-treated animals that reached end of 
gestation (Fig. 5A). Moreover, fetuses that received antibodies had less brain pathology overall, as only 1 
out of 7 fetuses (14%) had a brain pathology score of moderate (score of 3) or above, in contrast to 4/10 
(40%) of the control fetuses ((21), Figs. 5B, S7 and Table S3). Though its dam had no detectable viremia, 
it is possible that the moderate brain pathology score in one antibody-treated fetus (AB08-F) reflects 
earlier infection that was cleared by the time the fetus was harvested. Pathology scores of placenta and 
amnion were not significantly different between groups (Fig. S7 and Table S3). Finally, there was no 
correlation between maternal viremia and pathology scores; while aviremic animal AB05 had normal 
fetus and placenta, macaque AB07 was also aviremic but its fetus and placenta showed mild to moderate 
pathology scores, respectively; in contrast, the fetus of animal AB06, which had higher than 104 RNA 
copies/ml at peak maternal viremia, had normal brain findings but moderate placental pathology (Fig. 5B 
and Fig. S7). We conclude that maternal administration of Z004GRGR/LS + Z021GRLR/LS limits vertical 
transmission and fetal brain damage by ZIKV. 
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Discussion 
Recombinant antibodies represent an alternative to vaccines for at-risk populations. Passive immunization 
reduces or prevents ZIKV infection in nonpregnant rodents and macaques (23, 25, 26, 31, 32). In 
addition, antibodies diminish ZIKV viral burden in the placenta and fetal organs, and also reduce fetal 
demise in mouse pregnancy models (33-35). Some of these ZIKV mouse pregnancy models reproduce 
features of the human disease, including brain pathology (4-6). However, mice are not natural hosts for 
ZIKV, and the development of pathology typically requires an impaired immune system. As opposed to 
immunocompetent rodents, macaques can be infected readily with ZIKV and their pregnancies are 
anatomically and physiologically far more similar to humans (36). Whether antibodies can prevent fetal 
disease in macaques had not been determined. Our experiments show that the combination of two ZIKV 
neutralizing human monoclonal antibodies is sufficient to thwart or significantly reduce maternal viremia, 
prevent virus accumulation in fetal tissues and reduce fetal pathology following repeated ZIKV challenge 
in macaques. The results have many similarities, but also some differences, with results obtained using 
the ZIKV DNA vaccine VRC5283 that was tested in the same animal model of congenital ZIKV disease 
(21).  
VRC5283 is a DNA vaccine that produces subviral particles with pre-membrane, membrane and 
envelope proteins, is immunogenic in phase 1 clinical trial and is currently being evaluated in a phase 
2/2b (17, 37, 38). In the macaque pregnancy experiment with similar design to the present study, two 
doses of vaccine prior to ZIKV inoculation significantly reduced maternal viremia when animals were 
challenged between 4 days to 1 year after the 2nd immunization (21). Viremia was undetectable in 5 of 13 
animals (38%), a rate of protection comparable to the current antibody treatment study (37.5%; n=8).  In 
addition, in the ZIKV DNA vaccine study, the presence or absence of detectable viremia in vaccinated 
dams correlated with the titer of neutralizing antibody responses at the time of the first ZIKV challenge 
(i.e., animals with antibody titers above a threshold had no detectable viremia). For vaccinated animals 
with detectable viremia, the reduced viremia was always early (peak viremia  ≤ 5 days after ZIKV 
inoculation), and short in duration (≤ 14 days after the first ZIKV challenge), consistent with the observed 
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rapid augmentation of antiviral antibody and T-cell mediated immune responses in vaccinated animals 
after challenge (21).  
In the passive immunization studies with Z004 and Z021, antibodies failed to prevent viremia 
when nonpregnant macaques were inoculated intravenously with a high dose of virus (105 PFU; (23)). In 
contrast, we achieved an overall 40% protection from detectable viremia in 20 animals infected with a 
more moderate dose of 103 PFU of ZIKV administered subcutaneously (5 protected out of 12 
nonpregnant macaques and 3 protected out of 8 pregnant dams). This dose is still higher than the typical 
dose received from a mosquito bite, which in laboratory experiments was ~30 PFU for both the ZIKV 
isolates used in this study (39). This protection was observed irrespective of Fc domain mutations that 
modify Fc receptor binding. Neutralizing antibody levels on day of challenge were similar between 
antibody-treated animals with or without detectable viremia, and were ≥ 3 logs higher than the in vitro 
inhibitory concentration. However, animals showing low levels and even no ZIKV in plasma had 
detectable viral RNA in tissues. This indicates that in some animals the virus was able to spread despite 
high levels of the neutralizing antibodies in serum. These results contrast with earlier reports of sterilizing 
protection by antibodies under similar virus challenge conditions (subcutaneous inoculation with 103 
PFU). However, sampling was less frequent and over a shorter time period in those studies and therefore 
transient or delayed viremia may have gone undetected (25, 26). The delay in viremia in the current study, 
despite high levels of the 2 neutralizing antibodies in the circulation, suggests that following moderate to 
high-dose ZIKV inoculation, virus can still reach tissues and initiate replication, either because in some 
tissues antibodies did not penetrate sufficiently, or because certain cell types became infected via 
mechanisms (e.g. via different cell receptors) that are insufficiently captured in the standard in vitro 
neutralization assays. The delayed peak viremia (7-60 days post-inoculation) in the pregnant dams likely 
reflects burst of virus replication in such reservoirs, which then triggered the development of active 
immune responses. The observation of early fetal losses in 2 control fetuses and one antibody-treated 
dam, with high levels of virus in fetal or placental tissues, and rapid disappearance of plasma viremia 
following fetectomy, indicates the fetal-placental compartment as a possible reservoir that is shielded 
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from antiviral immune responses. The observation of delayed viremia also in antibody-treated 
nonpregnant macaques suggests the existence of additional reservoirs, of which the identification will 
improve our knowledge of ZIKV pathogenesis and our ability to develop intervention strategies.  
 Despite these differences in the kinetic of viremia, early versus delayed viremia in vaccinated 
versus antibody-treated pregnant dams, the reduced maternal viremia and associated improved fetal 
outcomes were similar in the two studies (21). Thus, the VRC5283 vaccine and the Z004GRLR/LS + 
Z021GRLR/LS antibodies are comparably efficacious vis-à-vis fetal protection, with each strategy having 
their intrinsic advantages and limitations in terms of speed of induction, potential for enhancement and 
durability of protective immunity.  
Dengue is a flavivirus closely related to ZIKV. Dengue virus re-infection can lead to antibody-
enhanced disease by a mechanism that is associated with serologic cross-reactivity between different 
dengue serotypes (40-42). Antibodies to dengue also cross-react with ZIKV and experiments in mice and 
with human placental explants have shown that ZIKV infection can be enhanced by antibodies in these 
systems (43-46). Conversely, antibodies to ZIKV that are maternally acquired cause more severe disease 
in mice infected with dengue (47). Finally, features of the antibodies that increase ZIKV infection in in 
vitro ADE assays correlate with an enhanced risk of Zika microcephaly in humans and brain pathology in 
macaque (22). Thus, even though preliminary epidemiologic studies in humans do not show ADE of 
ZIKV (48), the potential for enhancement is a safety concern for ZIKV vaccine development that clinical 
trials need to address. Since monoclonal antibodies that are Fc modified to prevent ADE can shield 
against ZIKV infection and fetal damage, they represent a potentially safe and efficacious alternative 
intervention strategy in the face of a ZIKV outbreak.  
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Fig. 1. Administration of Z004GRLR/LS + Z021GRLR/LS antibodies reduces magnitude and 
duration of ZIKV viremia in rhesus macaques. (A) Schematic of the experiment. Macaques 
were administered Fc-modified human monoclonal antibodies Z004 and Z021 one day prior to 
subcutaneous challenge with 103 PFU of Puerto Rican Zika virus (ZIKV-PR). (B) Antibody 
treatment alters plasma viral loads. Macaques received either the GRLR version of the antibodies 
(green), the GRLR/LS version (orange), or were left untreated (black). Shown are plasma ZIKV 
RNA levels over time as determined by qRT-PCR. (C) Peak plasma viral RNA levels are 
decreased in antibody treated macaques (based on panel B). In grey is the peak viral load of both 
Z004GRLR + Z021GRLR and Z004GRLR/LS + Z021GRLR/LS groups combined. The dotted line 
represents the limit of detection of the assay and samples with undetectable ZIKV were 
arbitrarily assigned a value equal to half of the limit of detection. (D) Peak plasma viremia is 
delayed in antibody treated macaques (based on panel B). Bars in C and D represent the mean; 
the p values were determined with the Mann-Whitney test. 
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Fig. 2. Zika viral RNA levels in tissues are decreased in antibody treated animals. (A) Viral 
RNA was measured in a panel of tissues obtained at euthanasia (day 26-29 post infection). 
Values represent log10 of viral RNA copies per gram of tissue, as determined by qRT-PCR. Data 
are represented as mean ± SD of triplicate measurements. In green are macaques treated with 
Z004GRLR + Z021GRLR and in black are untreated controls. (B) Shown for each macaque is the 
number of tissues with detectable viral RNA. Bars represent the mean; the p values was 
determined with the Mann-Whitney test. 
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Fig. 3. Mutations in Zika virus emerging in plasma from antibody treated macaques 
remain sensitive to Z004 and Z021. (A) Summary of the amino acid changing mutations in the 
envelope domain III (EDIII) of ZIKV. The virus EDIII region recognized by Z004 and Z021 was 
amplified and sequenced at peak plasma viremia. Shown is a graphic summary of the identified 
mutations. Note that V330L was also detected in one untreated macaque.  We were unable to 
amplify the EDIII from one sample with RNA copies/ml below 103. (B) The mutations are 
mapped on the structure of the sE dimer of ZIKV (PDB ID: 5JHM). The structures of the Z004-
related antibody Z006 (PDB ID:5VIG) and of Z021 (PDB ID:6DFI) in complex with the EDIII 
of ZIKV are structurally aligned to the sE dimer to show the location of residues T309 and V330 
relative to the binding sites of the antibodies. The ZIKV EDIII from the Z006-EDIII and Z021-
EDIII structures are omitted for clarity. (C) The epitopes of ZIKV EDIII recognized by the 
Z004-related antibody Z006 (in red), by Z021 (in blue) and by both antibodies (in purple) are 
shown. Residue T309 is highlighted. (D), Z004, Z021 and the two antibodies together (Z004 + 
Z021) neutralize RVPs corresponding to ZIKV wild type sequence or ZIKV mutated at the 
indicated residues. For Z004 + Z021, each of the antibodies is added at the indicated 
concentration (e.g., 10ng/ml contains 10ng/ml of Z004 plus 10ng/ml of Z021). Data are 
represented as mean ± SD of triplicates and a representative of two experiments is plotted. 
Values are relative to isotype control. 
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Fig. 4. Administration of Z004GRLR/LS + Z021GRLR/LS prevents or reduces ZIKV viral loads 
in pregnant macaques. (A) Schematic of the experiment. Pregnant macaques were administered 
Z004GRLR/LS + Z021GRLR/LS antibodies one day prior to subcutaneous challenge with 103 PFU of 
ZIKV on each of gestational days (GD) 30, 60 and 90. PR is Puerto Rican and BR is Brazilian 
ZIKV. Blood samples were obtained throughout the pregnancy. (B) Antibody treatment alters 
plasma viral loads. Macaques were either untreated (left) or treated with Z004GRLR/LS + 
Z021GRLR/LS (right). Shown are plasma ZIKV RNA levels over time. LOD is limit of detection. 
Asterisks indicate animals with early fetal death. (C) Peak plasma viral RNA levels are 
decreased in antibody treated macaques (based on panel b). The dotted line represents the limit 
of detection of the assay where samples with undetectable ZIKV were arbitrarily assigned a 
value equal to the limit of detection. (D) Peak plasma viremia is delayed in treated animals. (E) 
Overall plasma viral loads are decreased in treated macaques. (F) Duration of viremia is reduced 
in animals that received antibodies. Bars in C-F represent the mean; the p values were 
determined with the Mann-Whitney test. 
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Fig. 5. Protection of macaque fetuses by Z004GRLR/LS + Z021GRLR/LS. (A) With exception of 
AB02-F (i.e., the fetus of dam AB02), ZIKV RNA is undetectable in placental and fetal tissues 
from antibody treated dams. Viral RNA was measured in a panel of 17 fetal tissues and 3 fluids 
harvested at pregnancy termination. LN is lymph node, CSF is cerebrospinal fluid, AF is 
amniotic fluid, GI is gastro-intestinal, and CNS is central nervous system. * indicates the 2 
control animals and one antibody-treated animal with early fetal death. (B) Lower fetal brain 
pathology in animals receiving Z004GRLR/LS + Z021GRLR/LS. Triangles indicate fetuses whose 
dams had no detectable plasma viremia. Horizontal lines represent mean values and the p value 
was determined with the Mann-Whitney test. Pregnancies that terminated prematurely (GD60 or 
earlier) were omitted from this panel. Pathology scores of fetal tissues are summarized in Fig. 
S7. 
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Materials and Methods 
 
Cell lines 
Human embryonic kidney HEK-293-6E cells were cultured at 37˚C in 8% CO2, shaking at 120 rpm. The 
other cell lines were cultured at 37˚C in 5% CO2, without shaking: human hepatocytes Huh-7.5 cells were 
grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 1% nonessential amino acids 
(NEAA) and 5% FBS; human Lenti-X 293T cells were grown in DMEM supplemented with 10% FBS. 
 
Antibodies 
The human IgG1 antibodies Z004 and Z021 and their Fc-variants (GRLR and GRLR/LS) were previously 
described (23, 30). Z004GRLR and Z021GRLR were prepared by transient transfection of mammalian HEK-
293-6E cells with equal amounts of immunoglobulin heavy and light chain expression vectors. The 
supernatant was harvested after seven days and the antibodies purified using Protein G Sepharose 4 Fast 
Flow. LPS was removed with TritonX-114 and the antibodies concentrated in PBS. Z004GRLR/LS (TDI-Y-
001) and Z021GRLR/LS (TDI-Y-002) were produced by WuXi and provided by the Tri-Institutional 
Therapeutics Discovery Institute (TDI, New York). In TDI-Y-002, the Z021 heavy chain variable 
sequence was modified (C50V). 
 
Macaque infection experiments 
Animals and care 
All rhesus macaques (Macaca mulatta) in the study were born and raised in the conventional (i.e., not 
specific pathogen free) breeding colony at the California National Primate Research Center (CNPRC; 
Supplementary Table S4). While none of the animals were positive for type D retrovirus, SIV or simian 
lymphocyte tropic virus type 1, two animals in the pregnancy control group (C02 and C07) were 
seropositive for West Nile virus due to prior outdoor housing. All animals in the pregnancy experiment 
had prior pregnancies (range 2-10). 
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The CNPRC is accredited by the Association for Assessment and Accreditation of Laboratory Animal 
Care International (AAALAC).  Animal care was performed in compliance with the 2011 Guide for the 
Care and Use of Laboratory Animals provided by the Institute for Laboratory Animal Research. 
Macaques were housed indoor in stainless steel cages (Lab Product, Inc.) whose sizing was scaled to the 
size of each animal, as per national standards, and were exposed to a 12-hour light/dark cycle, 64-84°F, 
and 30-70% room humidity. Animals had free access to water and received commercial chow (high 
protein diet, Ralston Purina Co.) and fresh produce supplements. The study was approved by the 
Institutional Animal Care and Use Committee of the University of California, Davis. 
 
Experiments with nonpregnant macaques 
All 18 rhesus macaques (Macaca mulatta) were healthy juvenile males and females (~2 to 4 years of age).   
When necessary for inoculations or sample collections, macaques were immobilized with 10 mg/kg 
ketamine hydrochloride (Parke-Davis) injected intramuscularly after overnight fasting. Z004 and Z021 
antibodies were administered by the intravenous (i.v.) route to macaques at doses of 15 mg/kg body 
weight 24 hours before subcutaneous inoculation with Puerto Rican ZIKV (ZIKV-PR; 103 PFU, strain 
PRVABC-59; GenBank KU501215). For the experiments in Figure S2, two macaques were administered 
antibody Z021 (with wild type Fc) and infected intravenously with high dose of Brazilian ZIKV (ZIKV-
PR; 105 PFU, strain SPH2015; GenBank KU321639.1) similar to previously reported (23).  Macaques 
were evaluated at least daily for clinical signs of disease including poor appetence, stool quality, 
dehydration, diarrhea, and inactivity. None of the animals that received the antibodies developed any 
clinical signs, suggesting a good safety profile. Animals were sedated for antibody administration (minus 
24h), at time zero (virus inoculation), daily for 7 to 8 days, and then every few days for sample collection. 
EDTA-anti-coagulated blood samples were collected using venipuncture and plasma isolated. At the end 
of the study, animals were euthanized for tissue collection. The samples were processed, and the viral 
RNA measured from plasma and tissues as described below for pregnant macaques. 
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Experiments with pregnant macaques 
Time-mated breeding and pregnancy selection 
For time-mated breeding, the female macaques were monitored for reproductive cycle and at the time of 
optimal receptiveness, temporarily housed with breeding males to induce pregnancy. Gestational ages 
were determined from the menstrual cycle of the dam and the fetus length at initial ultrasound compared 
to growth data in the CNPRC rhesus macaque colony. Fetal health and viability were rechecked via 
ultrasound immediately before the first ZIKV inoculation (~ GD 30) and regularly thereafter.  
 
Antibody treatment and virus inoculations 
Z004 and Z021 antibodies were administered to macaques by the i.v. route at doses of 15 mg/kg body 
weight each by 24 hours before each virus inoculation. Each pregnant animal was inoculated with virus 3 
times. Whereas the normal gestation of rhesus macaques is 165 days, inoculations occurred at 
approximately GD 30, 60 and 90, corresponding to first and second trimester of human gestation. The GD 
30 and GD 90 inoculations were done with a 2015 Puerto Rico isolate (PRVABC-59; GenBank 
KU501215), while the GD 60 inoculation was done with a 2015 Brazil isolate (strain Zika 
virus/H.sapiens-tc/BRA/2015/Brazil_SPH2015; GenBank KU321639.1), the same strain as tested earlier 
in pregnant and nonpregnant animals (11, 27). The use of two strains was intended to mimic an endemic 
area where different variants may circulate. Aliquots of both virus stocks were kept frozen in liquid 
nitrogen, and a new vial was thawed shortly before each inoculation. For each inoculation, the inoculum 
was adjusted to 1,000 PFU in 0.5 ml of RPMI-1640 medium, then kept on wet ice and injected 
subcutaneously to simulate the route of mosquito feeding. This dose is higher than the typical dose 
received from a mosquito bite, which in laboratory vector competence experiments with Californian 
Aedes aegypti was ~30 PFU for both the ZIKV isolates used in this study (39). 
 
Sample collection and clinical observations and monitoring 
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Macaques were evaluated twice daily for clinical signs of disease including poor appetence, stool quality, 
dehydration, diarrhea, and inactivity. When necessary, macaques were immobilized with ketamine 
hydrochloride (Parke-Davis) at 10 mg/kg and injected intramuscularly after overnight fasting. Animals in 
both the ZIKV treated and placebo cohorts were sedated at days 0 (time of first virus inoculation; 
approximately GD 30), 2, 3, 5, 7, 14, 21, 30 (2nd ZIKV inoculation at GD60), 32, 37, 44, 51, 60 (3rd ZIKV 
inoculation; GD90), 62, 67, and then weekly until time of euthanasia between GD155-162, for sample 
collection and ultrasound monitoring of fetal health. The antibody-treated animals had additional time 
points of sedation for blood collection and IV antibody administration one day before each ZIKV 
inoculation. EDTA-anti-coagulated blood was collected using venipuncture at every time point for 
complete blood counts (with differential count), and a separate aliquot of blood was centrifuged for 10 
min at 800 g to separate plasma from cells. The plasma was spun an additional 10 min at 800 g to further 
remove cells, and aliquots were immediately frozen at -80°C. 
Ultrasound guided amniocentesis was conducted starting at day 14 after inoculation (GD44), and then at 
all time points listed above with exception of days 32 and 62 after initial infection. The amniocentesis was 
conducted using sterile techniques by inserting a 22 gauge, 1.5 inch spinal needle into the amniotic sac. 
The fetal heart rate was obtained before and after amniocentesis.  The area of umbilical entry through the 
amniotic sac was always avoided to prevent damage to the umbilical arteries and vein. Whenever 
possible, placental tissue was avoided during the collection of amniotic fluid. Amniotic fluid was spun to 
remove cellular debris, and the supernatant was aliquoted and immediately cryopreserved at -80°C for 
viral RNA assays.  
 
Necropsy and tissue collection  
All necropsies were performed by a board-certified anatomic pathologist and a pathology technician. For 
animals that had early fetal loss, the procedures described below were performed to the best extent 
possible based on fetal size. Hysterotomy was performed by a veterinary surgeon on the pregnant 
macaques under inhalation anesthesia. After collection of amniotic fluid and cord blood, the fetus was 
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euthanized with an overdose of sodium pentobarbital (≥120 mg/kg). Fetal and organ weights were 
measured with a scale, and crown-rump length, biparietal diameter, head height, head length, and femur 
length, were derived from caliper measurements. A detailed tissue dissection was performed. Except for 
some animals that had early fetal loss and were maintained several weeks after removal of the fetus, all 
other mothers were euthanized shortly after their fetus with an overdose of sodium pentobarbital for tissue 
collection.  
Each tissue was grossly evaluated in situ, and then excised, with further dissection with separate forceps 
and razor blades for each tissue to minimize risks for cross-contamination. Tissues were collected for 
viral analyses in RNAlater (according to manufacturer’s instructions); extra available samples were 
snapfrozen and stored at -70°C. Tissues were also preserved in 10% neutral buffered formalin and 
routinely paraffin-embedded and slides were created and routinely stained with hematoxylin and eosin 
(H&E).  
 
Isolation and quantitation of viral RNA from fluids and tissues for determination of infection status 
ZIKV RNA was isolated from samples and measured in triplicate by qRT-PCR according to methods 
described previously (27) modified to increase the initial volume of sample tested from 140 to 300 µl to 
increase sensitivity. According to the volume available, the limit of detection for plasma and amniotic 
fluid ranged from 1.5 to 2.3 log10 viral RNA copies per ml fluid. RNAlater preserved tissues were 
homogenized to a liquid state with glass beads (Fisher Scientific) or a 5 mm steel ball (Qiagen). For 
tissues, the limit of detection (LOD) varied depending on the weight of tissue sampled with a mean of 3.5 
log10 RNA copies/g of tissue, determined according to the calculations described in (49). 
For maternal plasma, amniotic fluid, fetal cord blood and fetal cerebrospinal fluid, all samples 
from both control and vaccine group animals that could be collected were tested.  For the 
maternal tissue samples, as maternal infection was not the main focus of this study, a limited 
selection of lymphoid tissues most likely to have viral RNA based on prior studies was tested (11, 27), 
with addition of uterus due to proximity to the placenta and fetus. For the analysis of fetal tissue samples 
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for viral RNA, we started our analysis with the control fetuses and tested 26 fetal and maternal-fetal-
interface (MFI) tissues, consisting of tissues most likely to contain viral RNA based on our prior study 
(11). Next we generated a heatmap and selected a list of 17 tissues consisting of those most likely to be 
infected and diagnosing the most infections in the control fetuses, with addition of brain regions most 
likely to have histological lesions in the current study (such as hippocampus), or found to be infected in 
human fetuses affected by CZS (50). The criteria to define infection were used systematically for both 
control and antibody treated group fetuses: a fetus was considered ZIKV-infected if at least one tissue had 
a consistent qRT-PCR signal (3/3 replicates positive for viral RNA); this situation applied to 11 of the 12 
control fetuses. In a rare case, when a fetus only had a sample with inconsistent qRT-PCR signal (1 out of 
3 replicates positive) while all other tissues were negative, retesting was performed, generally on a 
different aliquot. If the retest result was negative (3/3 replicates), the sample was considered not to 
contain detectable ZIKV RNA, if this occurred for all tissues from a fetus, the fetus was considered not 
infected. One control fetus (C07-F) and one antibody group fetus (AB05-F) met these criteria and were 
therefore considered uninfected. 
 
Histopathology 
Sections of fixed and embedded fetal tissues were stained with hematoxylin and eosin (H&E) and 
evaluated by a board-certified anatomic pathologist. Scoring of critical fetal tissues was done according to 
criteria outlined in Table S3.  
 
Virus sequencing 
For the detection of virus mutations at the envelope domain III (EDIII) region, ZIKV RNA was extracted 
at peak plasma viremia and Qiagen One-Step RT-PCR was performed using either of two primer sets 
targeting sequences surrounding the ZIKV EDIII region, as previously detailed (23). Due to low levels of 
viremia in some samples, reliable EDIII sequence information was not always obtained in samples with 
amounts below 103 RNA copies/ml plasma. Mutations reported are based on changes in the majority 
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nucleotide in sequencing chromatograms; concordant sequences in both directions were used to identify 
mutations. 
 
Reporter virus particles (RVPs) 
Luciferase encoding RVPs bearing the wild type or mutant ZIKV E proteins of interest were produced by 
co-transfection of Lenti-X-293T cells with plasmid pWNVII-Rep-REN-IB (WNV replicon expression 
construct; (51)) in combination with plasmids expressing flavivirus CprME (1 µg of pWNVII-Rep-REN-
IB and 3 µg of the CprME plasmid) as previously detailed (30).  
The plasmids for expression of wild type ZIKV CprME with E protein sequence corresponding to Puerto 
Rican ZIKV (strain PRVABC59) that was used in this study was generated from plasmid 
pZIKV/HPF/CprM*E* (30) by replacing a BspHI/SacII fragment with sequences corresponding to the 
PRVABC59 strain that were generated by PCR using oligos RU-O-24379 and RU-O-24380 and 
PRVABC59 derived cDNA as template. The resulting plasmid was designated 
pZIKV/HPF/CprM*PRVABC59E*. Assembly PCR-based site-directed mutagenesis was then used to 
introduce in pZIKV/HPF/CprM*PRVABC59E* the V330L, T309A, V330L/T309A and V330L/T309I 
mutations that resulted in plasmids pZIKV/HPF/CprM*PRVABC59E* (V330L), pZIKV/HPF/ 
CprM*PRVABC59E* (T309A), pZIKV/HPF/CprM*PRVABC59E* (V330L/T309A) and pZIKV/HPF/ 
CprM*PRVABC59E* (V330L/T309I). Similarly, the ZIKV RVPs encoding for the T335 mutations (Fig. 
S2) were generated by modifying plasmid  pZIKV/HPF/CprM*E* (30) to introduce the T335A and T335I 
modifications resulting in pZIKV/HPF/CprM*E* (T335A) and pZIKV/HPF/CprM*E* (T335I), 
respectively. The primers used for assembly PCR and mutagenesis are listed in Table S5. All PCR-
derived plasmid regions were verified by sequencing. 
 
In vitro neutralization assay 
RVP neutralization of luciferase-encoding RVPs by antibodies was performed with Huh-7.5 cells in 96-
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well plates, in triplicate, as previously detailed (30), and the luciferase activity was read using a FLUOstar 
Omega luminometer (BMG LabTech). The neutralization capacity of the antibodies against wild type or 
mutant RVPs was determined by the percentage of luciferase activity obtained relative to RVPs incubated 
with isotype control antibody 10-1074 (52). Representatives of at least two independent experiments are 
shown. 
 
Measurements of human IgG in macaque plasma 
ELISA was used for the detection of human IgG as previously detailed (30). Briefly, the biotinylated anti-
human IgG capture antibody was added to neutravidin-coated 96-well plates. Upon washes, the plates 
were blocked with 2% BSA, blotted, and then serial dilutions of the macaque plasma were added to the 
wells (5 steps of 1:4 dilutions in PBS-T, starting with 1:10). Each plate included serial dilutions of the 
standard, in duplicates (Z004 IgG, 11 steps of 1:3 dilutions in PBS-T, starting with 10 µg/ml). Plates were 
incubated for 1 hour at room temperature and washed prior to adding the detection reagent anti-human 
IgG-HRP. After washes, the reaction was developed with ABTS substrate (Life Technologies). 
 
Measurements of human IgG in mouse serum 
ELISA was used for the detection of human IgG as previously detailed (53). Briefly, FcRn/FcγR-
humanized mice were injected i.v. with 100 μg of Z004 or Z021 Fc variants. High-binding 96-well 
microtiter plates (Nunc) were coated overnight at 4°C with Neutravidin. All sequential steps were 
performed at room temperature. Plates were blocked for 1 hour with PBS/2% BSA and incubated with 
biotinylated goat anti–human IgG antibodies for 1 hour (5 μg/mL; catalog 109-066-170, Jackson 
ImmunoResearch). Serum samples were serially diluted and incubated for 1 hour, followed by incubation 
with horseradish peroxidase–conjugated anti–human IgG. After washes, the reaction was developed with 
the TMB peroxidase substrate system (KPL) and stopped with 2 M phosphoric acid. Αbsorbance at 450 
nm was immediately recorded using a SpectraMax Plus spectrophotometer (Molecular Devices), 
background absorbance from negative control samples was subtracted, and duplicate wells were averaged. 
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Statistical analyses 
Statistical analyses were with Prism 8 (GraphPad). 
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